Head-To-Head Contrast: NRx Pharmaceuticals (NRXP) and The Competition

NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) is one of 894 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its peers? We will compare NRx Pharmaceuticals to related companies based on the strength of its valuation, institutional ownership, analyst recommendations, risk, earnings, dividends and profitability.

Valuation & Earnings

This table compares NRx Pharmaceuticals and its peers gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
NRx Pharmaceuticals $1.23 million -$28.62 million -5.09
NRx Pharmaceuticals Competitors $17.36 billion $3.18 billion 555.16

NRx Pharmaceuticals’ peers have higher revenue and earnings than NRx Pharmaceuticals. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

NRx Pharmaceuticals has a beta of 2.11, suggesting that its share price is 111% more volatile than the S&P 500. Comparatively, NRx Pharmaceuticals’ peers have a beta of -0.05, suggesting that their average share price is 105% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for NRx Pharmaceuticals and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NRx Pharmaceuticals 1 1 6 0 2.62
NRx Pharmaceuticals Competitors 7850 13806 25845 1039 2.41

NRx Pharmaceuticals currently has a consensus price target of $35.00, suggesting a potential upside of 1,150.00%. As a group, “Pharmaceuticals” companies have a potential upside of 27.52%. Given NRx Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts clearly believe NRx Pharmaceuticals is more favorable than its peers.

Institutional and Insider Ownership

4.3% of NRx Pharmaceuticals shares are held by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 4.9% of NRx Pharmaceuticals shares are held by insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares NRx Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
NRx Pharmaceuticals -458.48% N/A -50.74%
NRx Pharmaceuticals Competitors -2,391.71% -206.09% -14.88%

Summary

NRx Pharmaceuticals peers beat NRx Pharmaceuticals on 7 of the 13 factors compared.

NRx Pharmaceuticals Company Profile

(Get Free Report)

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders, with a focus on depression and conditions involving suicidal ideation. Its programs are investigational and have not been established as approved treatments. The company’s candidates include NRX-100, a preservative-free formulation of ketamine, and NRX-101, an oral combination of D-cycloserine and lurasidone. NRx has studied these therapies for severe depression and bipolar depression, including in patients with suicidal ideation.

Receive News & Ratings for NRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.